Rufinamide

DRUG11 trials

Conditions

EpilepsyHealthy SubjectsLennox Gastaut SyndromeLennox-Gastaut SyndromePainPeripheral Nerve InjuriesRefractory Partial Onset SeizuresRefractory Partial Seizures

Phase 1

Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects

CompletedNCT02332174

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySeizures

Start: 2014-03-31End: 2014-06-30Updated: 2015-01-06

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

CompletedNCT06740825

Daiichi SankyoHealthy Subjects

Start: 2024-10-29End: 2024-12-09Updated: 2024-12-18

Phase 2

Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome

WithdrawnNCT02095899

University of ZurichPain, Peripheral Nerve Injuries

Start: 2014-03-31End: 2015-05-31Updated: 2015-07-21

Phase 3

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

CompletedNCT00334958

Eisai Inc.Epilepsy

Start: 2006-02-13End: 2009-05-20Updated: 2021-06-14

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

TerminatedNCT00448539

Eisai Inc.Refractory Partial Onset Seizures

Start: 2007-03-15End: 2010-05-14Updated: 2019-11-22

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

CompletedNCT01151540

Eisai Co., Ltd.Lennox-Gastaut Syndrome

Start: 2010-11-30End: 2013-08-31Updated: 2019-03-11

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

CompletedNCT01405053

Eisai Inc.Lennox-Gastaut Syndrome

Start: 2011-06-16End: 2015-11-02Updated: 2019-08-06

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

WithdrawnNCT04558580

University of South AlabamaRefractory Partial Seizures

Start: 2006-04-30End: 2008-12-31Updated: 2020-09-22

Unknown Phase

Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

CompletedNCT02175173

Eisai Co., Ltd.Lennox-Gastaut Syndrome

Start: 2013-06-13End: 2022-11-02Updated: 2023-02-21

Population Pharmacokinetics of Antiepileptic in Pediatrics

CompletedNCT03196466

Assistance Publique - Hôpitaux de ParisEpilepsy

Start: 2017-06-19End: 2023-06-15Updated: 2025-11-20

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

NCT03778424

Eisai Inc.Lennox Gastaut Syndrome

Updated: 2025-07-17

Related Papers

Novel seizure outcomes in patients with Lennox-Gastaut syndrome: Post hoc analysis of seizure-free days in rufinamide Study 303.

2019-03-1315 citations

Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303.

2018-09-2717 citations

Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study

European Journal of Paediatric Neurology2016-01-1131 citations